Microbix Biosystems (TSE:MBX) Stock Price Down 13.2% – Should You Sell?

Microbix Biosystems Inc. (TSE:MBX)’s stock price dropped 13.2% during trading on Thursday . The stock traded as low as C$0.23 and last traded at C$0.23. Approximately 173,500 shares changed hands during mid-day trading, an increase of 206% from the average daily volume of 56,636 shares. The stock had previously closed at C$0.27.

Microbix Biosystems Stock Performance

The stock has a market capitalization of C$31.17 million, a price-to-earnings ratio of -7.50 and a beta of 0.48. The company’s fifty day simple moving average is C$0.24 and its 200 day simple moving average is C$0.24. The company has a quick ratio of 5.57, a current ratio of 5.35 and a debt-to-equity ratio of 27.03.

Microbix Biosystems (TSE:MBX) last released its quarterly earnings data on Thursday, May 14th. The company reported C($0.01) EPS for the quarter. Microbix Biosystems had a negative net margin of 38.62% and a negative return on equity of 21.02%. The company had revenue of C$3.38 million during the quarter. On average, equities research analysts expect that Microbix Biosystems Inc. will post 0.02 earnings per share for the current year.

Microbix Biosystems Company Profile

Microbix develops proprietary biological technology solutions for human health and well-being, with about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows.